Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:NWBO
- CUSIP: N/A
- Web: www.nwbio.com
- Market Cap: $32.1 million
- Outstanding Shares: 186,061,000
- 50 Day Moving Avg: $0.18
- 200 Day Moving Avg: $0.36
- 52 Week Range: $0.14 - $0.98
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.11
- P/E Growth: 0.0000
- Annual Revenue: $623,000.00
- Price / Sales: 51.52
- Book Value: ($0.17) per share
- Price / Book: -1.02
- EBIDTA: ($79,080,000.00)
- Net Margins: -5,283.14%
- Return on Assets: -157.12%
- Current Ratio: 0.04%
- Quick Ratio: 0.04%
- Average Volume: 1.40 million shs.
- Beta: 1.75
- Short Ratio: 13.54
Frequently Asked Questions for Northwest Biotherapeutics (NASDAQ:NWBO)
What is Northwest Biotherapeutics' stock symbol?
Northwest Biotherapeutics trades on the NASDAQ under the ticker symbol "NWBO."
How were Northwest Biotherapeutics' earnings last quarter?
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm earned $0.39 million during the quarter, compared to analysts' expectations of $0.20 million. View Northwest Biotherapeutics' Earnings History.
Where is Northwest Biotherapeutics' stock going? Where will Northwest Biotherapeutics' stock price be in 2017?
0 brokerages have issued 12 month price objectives for Northwest Biotherapeutics' stock. Their forecasts range from $0.61 to $0.61. On average, they expect Northwest Biotherapeutics' stock price to reach $0.61 in the next year. View Analyst Ratings for Northwest Biotherapeutics.
Who are some of Northwest Biotherapeutics' key competitors?
Some companies that are related to Northwest Biotherapeutics include Sierra Oncology (SRRA), ContraFect Corp (CFRX), KemPharm (KMPH), CASI Pharmaceuticals (CASI), Galmed Pharmaceuticals Ltd (GLMD), Eiger Biopharmaceuticals (EIGR), Flex Pharma (FLKS), GTx (GTXI), Bioline RX Ltd (BLRX), Zosano Pharma Corp (ZSAN), Prima BioMed Ltd (PBMD), XOMA (XOMA), vTv Therapeutics (VTVT), TRACON Pharmaceuticals (TCON), Inotek Pharmaceuticals Corp (ITEK), OvaScience (OVAS), ADMA Biologics (ADMA) and Medgenics (GNMX).
How do I buy Northwest Biotherapeutics stock?
Shares of Northwest Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Northwest Biotherapeutics stock cost?
One share of Northwest Biotherapeutics stock can currently be purchased for approximately $0.17.
Consensus Ratings for Northwest Biotherapeutics (NASDAQ:NWBO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||$0.61 (253.62% upside)|
Analysts' Ratings History for Northwest Biotherapeutics (NASDAQ:NWBO)
(Data available from 5/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/15/2016||S&P Equity Research||Lower Price Target||$0.73 -> $0.61||N/A|
Earnings History for Northwest Biotherapeutics (NASDAQ:NWBO)Earnings History by Quarter for Northwest Biotherapeutics (NASDAQ:NWBO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/10/2015||Q2 2015||($0.32)||($0.54)||$0.20 million||$0.39 million||View||N/A|
|5/15/2014||Q1 2014||($0.33)||($0.46)||$0.20 million||View||N/A|
Earnings Estimates for Northwest Biotherapeutics (NASDAQ:NWBO)
Current Year EPS Consensus Estimate: $-1.8500 EPS
Next Year EPS Consensus Estimate: $-1.6000 EPS
Dividend History for Northwest Biotherapeutics (NASDAQ:NWBO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Northwest Biotherapeutics (NASDAQ:NWBO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Northwest Biotherapeutics (NASDAQ:NWBO)
Latest Headlines for Northwest Biotherapeutics (NASDAQ:NWBO)
|Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017|
finance.yahoo.com - May 24 at 10:20 AM
|Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ...|
www.nasdaq.com - May 23 at 6:29 PM
|Northwest Biotherapeutics (NWBO) Receiving Somewhat Positive Media Coverage, Analysis Shows|
www.americanbankingnews.com - April 28 at 1:12 PM
|Northwest Biotherapeutics (NWBO) Earning Positive News Coverage, Report Finds|
www.americanbankingnews.com - April 25 at 8:02 PM
|Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017|
finance.yahoo.com - April 20 at 7:02 PM
|Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K|
finance.yahoo.com - April 18 at 10:04 AM
|Northwest Biotherapeutics (NWBO) Earning Very Favorable News Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 17 at 12:34 PM
|Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse|
finance.yahoo.com - April 7 at 11:37 AM
|Novocure Glioblastoma Drug Offers Survival Benefits|
www.investopedia.com - April 3 at 6:17 PM
|Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma|
www.bizjournals.com - March 31 at 9:08 AM
|Northwest closes $7.5M capital raise - Seeking Alpha|
seekingalpha.com - March 24 at 11:52 PM
|NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors|
finance.yahoo.com - March 23 at 7:28 PM
|NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an|
biz.yahoo.com - March 23 at 7:28 PM
|NW BIO Announces Registered Direct Offering Of $7.5 Million|
us.rd.yahoo.com - March 17 at 7:06 PM
|Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash|
www.thestreet.com - March 16 at 7:40 PM
|BRIEF-NW Bio reaches agreement with convertible note holders|
www.reuters.com - March 10 at 8:41 PM
|8:16 am Northwest Biotherapeutics signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors, holder of $11 mln of the co's convertible senior notes|
us.rd.yahoo.com - March 10 at 8:41 PM
|NW Bio Reaches Agreement With Convertible Note Holders|
finance.yahoo.com - March 10 at 9:21 AM
|NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi|
biz.yahoo.com - March 7 at 6:47 PM
|Biotech Stocks under Scanner -- ACADIA Pharma, Clovis Oncology, Galena Biopharma, and Northwest Biotherapeutics|
www.bizjournals.com - February 21 at 5:56 PM
|FDA lifts hold on Northwest Bio’s brain cancer immunotherapy trial|
www.bizjournals.com - February 9 at 8:01 PM
|Northwest Bio Spikes on Lifting of Clinical Hold (NWBO)|
www.investopedia.com - February 7 at 9:32 PM
|FDA Lifts Hold on Northwest Bio Cancer Drug Trial|
www.investopedia.com - February 7 at 4:30 PM
|BRIEF-NW bio announces lifting of clinical hold on DCVax -l phase III trial by FDA|
www.reuters.com - February 6 at 7:01 PM
|NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached|
finance.yahoo.com - February 6 at 7:01 PM
|9:31 am Northwest Biotherapeutics provides a further update about the Co's Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer; announces lifting of clinical hold on DCVax-l phase III trial by FDA|
finance.yahoo.com - February 6 at 7:01 PM
|Flu Case Grinds Small Biotech to a Halt|
blogs.wsj.com - January 23 at 7:17 PM
|NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure|
biz.yahoo.com - January 23 at 9:49 AM
|NW Bio Presenting At Phacilitate Immunotherapy World Conference|
finance.yahoo.com - January 18 at 7:33 PM
Northwest Biotherapeutics (NWBO) Chart for Friday, May, 26, 2017